Apogee Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• APG777 · Oncology
  APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3.

Phase 1 pipeline

• APG990

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Apogee Therapeutics, Inc. portfolio CI brief
• Apogee Therapeutics, Inc. pipeline updates RSS